Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
RESEARCH TOOLSreports
Aprea Therapeutics (APRE) Stock Price & Analysis
426 Followers
APRE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.78 - $8.85
Previous Close$5.37
Volume5.64K
Average Volume (3M)33.48K
Market Cap
$27.69M
Enterprise Value$7.55M
Total Cash (Recent Filing)$21.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.3
Beta1.09
Next Earnings
May 13, 2024EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding5,430,215
10 Day Avg. Volume5,447
30 Day Avg. Volume33,483
Standard Deviation0.27
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.64
Price to Sales (P/S)2071.78
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.65
Enterprise Value/Gross Profit12.95
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$15.67Price Target Upside207.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Aprea Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentFDA recently cleared the IND application for APR-1051, the company's best-in-class WEE1 inhibitor, advancing it to a biomarker driven Phase 1 trial.
Investment OpportunityThe valuation gap between Aprea and Zentalis presents an opportunity, with Aprea's market cap significantly lower despite promising preclinical results.
Product PipelineUpdates across programs underscore pipeline potential, with several promising developments in DNA Damage Response-focused anti-cancer platform.
Bears Say
Competitive LandscapeCompeting molecules from Repare, AstraZeneca, and Bayer have faced toxicity issues, particularly with anemia, potentially limiting their therapeutic use.
Corporate ActionsCompany completed 1:20 reverse split, typically a move made by companies facing stock price pressures or to maintain compliance with exchange listing requirements.
Drug Development ConcernsZentalis' Zn-c3 faces toxicity issues due to off-target PLK activity, necessitating intermittent dosing which is less ideal than continuous dosing.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $2.78 and its highest was $8.85 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Currently, no data Available
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is May 13, 2024 which is in 19 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Mar 26, 2024. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.767 by -$0.153.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -$0.76.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 5,430,215 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.767. Following the earnings report the stock price went down -2.632%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Among the largest hedge funds holding Aprea Therapeutics Inc’s share is Blackstone Inc.. It holds Aprea Therapeutics Inc’s shares valued at N/A.
---
Aprea Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (207.25% Upside)
$15.67 (207.25% Upside)
Blogger Sentiment
Bullish
APRE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 16.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $122.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.9%
Last 30 Days ▲ 38.1%
Last 30 Days ▲ 38.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.02%
12-Months-Change
Fundamentals
Return on Equity
-63.19%
Trailing 12-Months
Asset Growth
-24.89%
Trailing 12-Months
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
---
APRE Stock 12 Months Forecast
Average Price Target
$15.67
▲(207.25% Upside)
Technical Analysis
Best Analysts Covering APRE
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+13.97%
reiterated a buy rating 14 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +13.97% per trade.
---